City of Hope, a world-renowned independent research and treatment center
Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis
DURHAM, N.C.–(BUSINESS WIRE)–December 9, 2020 — Mycovia Pharmaceuticals, Inc. (“Mycovia”),
Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd.
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) — MediciNova,
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
February 19, 2019 — Pfizer Inc. (NYSE: PFE) and Eli
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in
X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial
CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.
Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 23, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a
Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough
REDWOOD CITY, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) — Menlo